Markets
Harrow Stock Soars 11% After Its Earnings Report — But It Cuts Its Annual Forecast
Quarterly revenue grew 38.6%, while the eye-drug company lowered its annual adjusted earnings target to more than $40 million.
Harrow (HROW) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Quarterly revenue grew 38.6%, while the eye-drug company lowered its annual adjusted earnings target to more than $40 million.
Earnings
Management emphasized post-injection comfort and plans no repeat study, while lowering its full-year adjusted earnings outlook.
Earnings
Sales rose 39%, but meeting the annual revenue forecast requires roughly 37% to 52% growth in the fourth quarter.
SEC Filings
The company expects the dry eye nasal spray to add more than $30 million in 2027 revenue; Viatris keeps Japan.